加味芍甘附子汤干预RA寒证肠粘膜免疫稳态的机制研究

注册号:

Registration number:

ITMCTR2100005071

最近更新日期:

Date of Last Refreshed on:

2021-07-18

注册时间:

Date of Registration:

2021-07-18

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

加味芍甘附子汤干预RA寒证肠粘膜免疫稳态的机制研究

Public title:

Study on the mechanism of modified Shaogan Fuzi decoction on intestinal mucosal immune homeostasis in RA Cold Syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

加味芍甘附子汤干预RA寒证肠粘膜免疫稳态的机制研究

Scientific title:

Study on the mechanism of modified Shaogan Fuzi decoction on intestinal mucosal immune homeostasis in RA Cold Syndrome

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100048846 ; ChiMCTR2100005071

申请注册联系人:

王海瑜

研究负责人:

王海瑜/侯秀娟

Applicant:

Wang Haiyu

Study leader:

Wang Haiyu/Hou Xiujuan

申请注册联系人电话:

Applicant telephone:

+86 15901279198

研究负责人电话:

Study leader's telephone:

+86 15901279198

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15901279198@163.com

研究负责人电子邮件:

Study leader's E-mail:

15901279198@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号

研究负责人通讯地址:

北京市朝阳区北三环东路11号

Applicant address:

11 North Third Ring Road East, Chaoyang District, Beijing, China

Study leader's address:

11 North Third Ring Road East, Chaoyang District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学

Applicant's institution:

Beijing University of traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

JDF-IRB-2021050701

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

东方医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of Dongfang Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990/1/1 0:00:00

伦理委员会联系人:

夏芸

Contact Name of the ethic committee:

Xia Yun

伦理委员会联系地址:

北京市丰台区芳星园一区6号

Contact Address of the ethic committee:

6 Zone 1, Fangxing Garden, Fengtai District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医药大学东方医院

Primary sponsor:

DongFang Hospital of Beijing University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

北京市丰台区方庄芳星园一区六号

Primary sponsor's address:

6 Zone 1, Fangxing Garden, Fengtai District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东方医院

具体地址:

丰台区方庄芳星园一区六号

Institution
hospital:

DongFang Hospital of Beijing University of traditional Chinese Medicine

Address:

6 Zone 1, Fangxing Garden, Fengtai District

经费或物资来源:

研究生课题经费

Source(s) of funding:

Postgraduate research funds

研究疾病:

类风湿关节炎

研究疾病代码:

Target disease:

rheumatoid arthritis

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

其它

Others

研究目的:

类风湿关节炎寒证存在肠粘膜免疫稳态失衡,TLR4-MyD88-NF-κBp65信号通路及Th17/Treg的失衡参与其中,紊乱的菌群可使肠粘膜通透性增加,条件致病菌移位,引发自身免疫性炎症,参与了RA的病理过程。本研究目的是收集RA寒证患者与健康对照组,初步探索肠粘膜免疫稳态的变化。以上研究将为中医辨证治疗RA提供更多的理论依据。

Objectives of Study:

The imbalance of intestinal mucosal immune homeostasis exists in cold syndrome of rheumatoid arthritis, in which the imbalance of TLR4-MyD88-NF- κ Bp65 signal pathway and Th17/Treg is involved. Disordered flora can increase intestinal mucosal permeability, translocate conditional pathogenic bacteria, cause autoimmune inflammation, and participate in the pathological process of RA. The purpose of this study was to collect patients with RA cold syndrome and healthy controls to explore the changes of intestinal mucosal immune homeostasis. The above research will provide more theoretical basis for TCM syndrome differentiation and treatment of RA.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合上述RA分类标准; 2.符合中医证候诊断标准; 3.符合病情判断标准:DAS28>3.2(活动期); 4.年龄18-70岁; 5.近1周未饮用酸奶; 6.近三个月未服用抗生素; 7.签署知情同意书。

Inclusion criteria

1. Meet the above RA classification criteria; 2. Meet the diagnostic criteria of TCM syndromes; 3. Meet the criteria for judging the disease: DAS28 > 3.2 (active stage); 4. Aged from 18 to 70 years; 5. Not drink yogurt for nearly 1 week; 6. Not take antibiotics in the past three months; 7. Signed informed consent.

排除标准:

1.有炎症性肠病、肠易激综合征、持久性、传染性胃肠炎、结肠炎或胃炎的患者; 2.合并有心血管、脑血管、肺、肝、肾和造血系统等疾病及精神病患者; 3.合并有其他风湿性疾病如系统性红斑狼疮、干燥综合征等; 4.人绒毛膜促性腺激素检查阳性; 5.哺乳期。

Exclusion criteria:

1. Patients with inflammatory bowel disease, irritable bowel syndrome, persistent, transmissible gastroenteritis, colitis or gastritis; 2. Patients with cardiovascular, cerebrovascular, pulmonary, liver, kidney and hematopoietic system diseases and psychosis; 3. Patients with other rheumatic diseases such as systemic lupus erythematosus, Sjogren's syndrome, etc; 4. Positive human chorionic gonadotropin test; 5. Lactation period.

研究实施时间:

Study execute time:

From 2021-01-01

To      2021-12-31

征募观察对象时间:

Recruiting time:

From 2021-01-01

To      2021-12-31

干预措施:

Interventions:

组别:

对照组

样本量:

10

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

试验组

样本量:

30

Group:

experimental group

Sample size:

干预措施:

加味芍甘附子汤

干预措施代码:

Intervention:

modified Shaogan Fuzi decoction

Intervention code:

样本总量 Total sample size : 40

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东方医院

单位级别:

三甲

Institution/hospital:

DongFang Hospital of Beijing University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

连蛋白

指标类型:

主要指标

Outcome:

zonulin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

辅助性T细胞17

指标类型:

主要指标

Outcome:

T help 17 cells

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

核转录因子kappa -Bp65

指标类型:

主要指标

Outcome:

nuclear factor-kappa Bp65

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪便球杆比

指标类型:

主要指标

Outcome:

Proportion of fecal cocci and bacilli

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

D-乳酸

指标类型:

主要指标

Outcome:

D-LA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

二胺氧化酶

指标类型:

主要指标

Outcome:

diamine oxidase

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪便PH值

指标类型:

主要指标

Outcome:

Fecal PH value

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

调节性T细胞

指标类型:

主要指标

Outcome:

Regulatory cells

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

髓样分化因子88

指标类型:

主要指标

Outcome:

myeloid differentiation factor 88

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Toll样受体4

指标类型:

主要指标

Outcome:

Toll-like receptor 4

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

会议报告或者论文发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Meeting report or article publication

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表采集原始数据,定期将原始数据录入数据管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The original data is collected in the Case Record Form and entered into the data management system regularly.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统